4th Quarter - Report

KNIGHT CAPITOL CONSULTANTS for INDIVIOR, INC.

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Potential additional funding for opioid overuse treatment activities for FY 2020 (PL 116-196, Consolidated Appropriations Act of 2021).

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Senator Orrin G. Hatch

Contacted: Drug Enforcement Administration (DEA); SENATE; Justice, Dept of (DOJ); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Omnibus legislation affecting prescription drug pricing (Senate HELP -Lower Healthcare Costs Act (S. 1895), Senate Finance - S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Senator Orrin G. Hatch (1999-2007)

Contacted: SENATE; Justice, Dept of (DOJ); HOUSE OF REPRESENTATIVES; Drug Enforcement Administration (DEA)

Bills named: S. 2543 (116th), H.R. 3 (116th), S. 1895 (116th)

Alcohol and Drug Abuse ALC

Implementation of the Support for Patients and Communities Act (P.L. 115-271), including section 3204; funding levels and distribution of funding for treatment of opioid overuse disorder (OUD) (including any successor legislation to PL 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act; PL 116-127,Families First Coronavirus Response Act; PL 116-136, CARES Act; and HR 133, Consolidated Appropriations Act of 2021, PL 116-196.)

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Senator Orrin G. Hatch

Contacted: Justice, Dept of (DOJ); HOUSE OF REPRESENTATIVES; SENATE; Drug Enforcement Administration (DEA)

Bills named: H.R. 133 (116th)

Health Issues HCR

DEA implementation of the SECURE Act and specifically Section 3204 addressing specialty pharmacy delivery providerS of long-acting injectable buprenorphine products. Fairness in Orphan Drug Exclusivity Act, H.R. 4712/S. 3271, included in H.R. 133, Consolidated Appropriations Act of 2021, PL 116-196).

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Senator Orrin G. Hatch

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Drug Enforcement Administration (DEA); Justice, Dept of (DOJ)

Bills named: S. 3271 (116th), H.R. 133 (116th), H.R. 4712 (116th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.